Alboko esklerosi amiotrofikoa
- June Landa Alberdi 1
- Larraitz Leunda Eizmendi 1
- Miren Ercilla Liceaga 1
- Maitane Umerez Igartua 1
- Aitziber Lizardi Mutuberria 1
- Miren Josune Garcia de Andoin Barandiaran 1
- Mikel Urretavizcaya Anton 1
- 1 Donostia Unibertsitate Ospitaleko farmazialariak
ISSN: 2530-9412
Año de publicación: 2019
Volumen: 3
Número: 2
Páginas: 87-90
Tipo: Artículo
Otras publicaciones en: Osagaiz: osasun-zientzien aldizkaria
Resumen
Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor system, causing muscle weakness, which can lead to paralysis. Patients can present difficulties in oral communication, swallowing, motor autonomy and breathing. However, sensitivity, sphincter control and eye muscles’ activity are preserved. It’s an incurable disease, and there is only one drug in the market that can extend longevity: riluzole. The life expectancy is short, causing death within 4-5 years in most patients.